Medical research article on Iberdomide Plus Daratumumab and Dexamethasone for multiple myeloma treatment.
Articles / Hematology 10/08/2026

Iberdomide Plus Daratumumab and Dexamethasone Shows Positive Results in Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

Key Points

  • ZDd reduced the risk of disease progression or death by 51% vs. DVd in patients with RRMM.
  • Median PFS was 42 months with ZDd vs. 20 months with DVd (HR, 0.49; p<0.000001).
  • Iberdomide-based therapy improved MRD-negative complete response, supporting its FDA accelerated approval in RRMM.
  • Neutropenia, infections, and thromboembolic events were important safety considerations with ZDd.

On October 8, 2026, Bristol Myers Squibb announced positive topline results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide in combination with daratumumab and dexamethasone (ZDd) in patients with relapsed or refractory multiple myeloma (RRMM). The randomized, open-label study enrolled 800 patients who had received one to two prior lines of anti-myeloma therapy and had progressive disease. Patients were randomized to ZDd or daratumumab, bortezomib, and dexamethasone (DVd), with treatment continued until disease progression or unacceptable toxicity.

At a median follow-up of 23 months, ZDd demonstrated a statistically significant improvement in progression-free survival (PFS), one of the study’s dual primary endpoints. Median PFS was 42 months with ZDd compared with 20 months with DVd, corresponding to a hazard ratio of 0.49 (p < 0.000001) and a 51% reduction in the risk of disease progression or death. 

The findings build on previously reported results demonstrating improved minimal residual disease (MRD)-negative complete response with ZDd versus DVd, which supported the U.S. Food and Drug Administration’s accelerated approval of iberdomide in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

Safety Findings

The EXCALIBER-RRMM study included additional secondary endpoints, including overall survival, overall response rate, sustained MRD negativity, and safety. The company reported that the safety profile of iberdomide in combination with standard therapies was consistent with previously reported findings. Clinically relevant toxicities included neutropenia and infections. In the reported safety population, all-grade neutropenia occurred in 90.2% of patients receiving iberdomide, with Grade 3 and Grade 4 neutropenia reported in 30.9% and 53.4%, respectively. Febrile neutropenia occurred in 5.4%. Infections occurred in 78.9% of patients, including Grade 3 infections in 35.8% and serious infections in 40%.

Thromboembolic events also remain an important consideration with iberdomide-based therapy. In the EXCALIBER-RRMM safety population, venous thromboembolic events occurred in 6.4% of patients receiving iberdomide with daratumumab and dexamethasone despite mandatory thromboprophylaxis, while arterial thromboembolic events occurred in 3.4%. The prescribing information recommends thromboprophylaxis based on individual patient risk factors, along with monitoring for thromboembolic complications. Iberdomide is also subject to a restricted distribution program because of embryo-fetal toxicity, with pregnancy testing and contraception requirements for patients of reproductive potential.

Clinical Implications

Full results from EXCALIBER-RRMM are expected to be presented at the 68th Annual Meeting of the American Society of Hematology (ASH). The findings provide confirmatory evidence that the improvement in MRD-negative response observed with iberdomide-based therapy translates into a clinically meaningful PFS benefit compared with DVd in patients with RRMM treated as early as first relapse. Further follow-up will help characterize overall survival and the durability of disease control with the regimen.